Predictive Oncology (AGPU) Stock Price, News & Analysis

Company Overview

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts. Predictive Oncology offers services and tools designed to help biopharmaceutical companies and research organizations evaluate therapeutic candidates and develop companion diagnostic strategies, leveraging a mix of experimental assays and data-driven analysis to generate actionable insights for oncology programs.

As a publicly traded company, Predictive Oncology works with commercial and research partners in the life sciences ecosystem. Publicly available, detailed historical background and current leadership information were limited at the time of this summary; readers seeking executive biographies, recent corporate developments or a full corporate history should consult the company’s regulatory filings and investor relations materials for the most current and authoritative information.

Key Stats

• Today's Range: $4.90 to $5.50
• 50-Day Range: $1.41 to $8.75
• 52-Week Range: $1.03 to $32.10
• Volume: 365,152 shs
• Average Volume: 2.52 million shs
• Market Capitalization: $30.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Predictive Oncology Stock Analysis - MarketRank™

Predictive Oncology scored higher than 7% of companies evaluated by MarketBeat, and ranked 50th out of 59 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Predictive Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Predictive Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Predictive Oncology is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Predictive Oncology is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Predictive Oncology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AGPU.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Predictive Oncology does not currently pay a dividend.

Dividend Growth

Predictive Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.13

News Sentiment

Predictive Oncology has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Predictive Oncology this week, compared to 2 articles on an average week.

Search Interest

29 people have searched for AGPU on MarketBeat in the last 30 days. This is an increase of 263% compared to the previous 30 days.

MarketBeat Follows

1 people have added Predictive Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Predictive Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.21% of the stock of Predictive Oncology is held by insiders.

Percentage Held by Institutions

9.04% of the stock of Predictive Oncology is held by institutions.

AGPU Stock Analysis - Frequently Asked Questions

How have AGPU shares performed this year?

Predictive Oncology's stock was trading at $5.04 on January 1st, 2026. Since then, AGPU shares have increased by 7.7% and is now trading at $5.43.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:AGPU) issued its quarterly earnings results on Tuesday, March, 31st. The company reported $122.75 EPS for the quarter. The firm had revenue of $0.01 million for the quarter.

How do I buy shares of Predictive Oncology?

Shares of AGPU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AGPU
• CIK: 1446159
• Web: N/A
• Phone: (651) 389-4800
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($12.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$233.10 million
• Net Margins: -185,476.72%
• Pretax Margin: -185,860.92%
• Return on Equity: N/A
• Return on Assets: -970.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.02
• Quick Ratio: 10.02

Sales & Book Value

• Annual Sales: $125.28 thousand
• Price / Sales: 240.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.69 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 5,539,000
• Free Float: 5,472,000
• Market Cap: $30.08 million
• Optionable: N/A
• Beta: 3.45